CO5640134A2 - Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x - Google Patents
Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico xInfo
- Publication number
- CO5640134A2 CO5640134A2 CO06005238A CO06005238A CO5640134A2 CO 5640134 A2 CO5640134 A2 CO 5640134A2 CO 06005238 A CO06005238 A CO 06005238A CO 06005238 A CO06005238 A CO 06005238A CO 5640134 A2 CO5640134 A2 CO 5640134A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- group
- pyridylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
1.- Un compuesto de fórmula I en donde:R1 se selecciona de fenil(1-4C)alquilo en donde el fenilo se sustituye en forma opcional por (1-4C)alcoxicarbonilo o un grupo de fórmula NRaRb en la cual Ra y Rb representan independientemente H ó (1-4C)alquilo;heteroaril(1-4C)alquilo en donde el heteroarilo se sustituye en forma opcional por (1-4C)alquilo o un grupo de fórmula NRaRb en la cual Ra y Rb representan independientemente H ó (1-4C)alquilo; o un grupo (1-6C)alquilo, el cual se sustituye en forma opcional por uno o más de los siguientes: fluoro, (1-4C)alcoxicarbonilo, (1-3C)alquiltio ó (1-3C)alcoxi sustituido en forma opcional por uno o más fluoro;R2 es fenilo;R3 se selecciona de fenilo, indol ilo o benzofuranilo cada uno sustituido en forma opcional por uno o más de los siguientes: (1-3C)alcanoilo, (1-4C)alcoxi sustituido en forma opcional por uno o más fluoro; (1-3C)alquiltio; o un grupo de fórmula NRaRb, en la cual Ra y Rb representan independientemente H, (1-3C)alquilo o (1-3C)alcanoilo o Ra y Rb junto con el átomo de nitrógeno al cual se unen, representan morfolino;X es O ó S, o su sal farmacéuticamente aceptable, o su solvato, o un solvato de tal sal.2.- Un compuesto de acuerdo con la reivindicación 1 en donde X es O.3.- Un compuesto de acuerdo con la reivindicación 1 en donde X es S.4.- Un compuesto de acuerdo con cualquier reivindicación precedente en la cual R1 se selecciona de metilo, etilo, propilo, butilo, 2-metoxietilo, 2,2,2-trifluoroetilo, bencilo, 4-piridilmetilo, 3-piridilmetilo ó 6-amino-3-piridilmetilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640134A2 true CO5640134A2 (es) | 2006-05-31 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06005238A CO5640134A2 (es) | 2003-07-11 | 2006-01-20 | Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (es) |
| EP (1) | EP1646625B1 (es) |
| JP (1) | JP2007521313A (es) |
| KR (1) | KR20060034284A (es) |
| CN (1) | CN100478340C (es) |
| AR (1) | AR045720A1 (es) |
| AT (1) | ATE399776T1 (es) |
| AU (1) | AU2004256000B2 (es) |
| BR (1) | BRPI0412479A (es) |
| CA (1) | CA2532068A1 (es) |
| CO (1) | CO5640134A2 (es) |
| DE (1) | DE602004014772D1 (es) |
| ES (1) | ES2308205T3 (es) |
| GB (1) | GB0316237D0 (es) |
| HK (1) | HK1088318A1 (es) |
| IL (1) | IL172759A0 (es) |
| IS (1) | IS8291A (es) |
| MX (1) | MXPA06000447A (es) |
| NO (1) | NO20060080L (es) |
| RU (1) | RU2006102129A (es) |
| SA (1) | SA04250203B1 (es) |
| TW (1) | TW200507836A (es) |
| UA (1) | UA82108C2 (es) |
| UY (1) | UY28407A1 (es) |
| WO (1) | WO2005005416A1 (es) |
| ZA (1) | ZA200600229B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2592771A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| WO2007002654A2 (en) * | 2005-06-28 | 2007-01-04 | Daiichi Sankyo Company, Limited. | Lxr ligand testing method |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| WO2008103818A1 (en) * | 2007-02-21 | 2008-08-28 | University Of Louisville Research Foundation | Therapeutic cotinine compositions |
| PT2868315T (pt) | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| WO2009097443A2 (en) * | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| PE20110570A1 (es) | 2008-07-01 | 2011-08-26 | Genentech Inc | Heterociclos biciclicos sustituidos |
| US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| JP2023509845A (ja) | 2019-12-13 | 2023-03-10 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2234300T3 (es) * | 1998-10-08 | 2005-06-16 | Smithkline Beecham Plc | 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa. |
| CA2377999A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc | Compositions and methods for raising hdl cholesterol levels |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en not_active Expired - Lifetime
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en active IP Right Grant
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Application Discontinuation
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
- 2006-08-07 HK HK06108722.2A patent/HK1088318A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200507836A (en) | 2005-03-01 |
| ZA200600229B (en) | 2007-04-25 |
| UY28407A1 (es) | 2005-02-28 |
| NO20060080L (no) | 2006-02-08 |
| SA04250203B1 (ar) | 2008-02-25 |
| MXPA06000447A (es) | 2006-04-07 |
| GB0316237D0 (en) | 2003-08-13 |
| BRPI0412479A (pt) | 2006-09-19 |
| ES2308205T3 (es) | 2008-12-01 |
| EP1646625A1 (en) | 2006-04-19 |
| IL172759A0 (en) | 2006-04-10 |
| CN1820003A (zh) | 2006-08-16 |
| EP1646625B1 (en) | 2008-07-02 |
| ATE399776T1 (de) | 2008-07-15 |
| RU2006102129A (ru) | 2006-08-27 |
| AR045720A1 (es) | 2005-11-09 |
| CN100478340C (zh) | 2009-04-15 |
| UA82108C2 (uk) | 2008-03-11 |
| CA2532068A1 (en) | 2005-01-20 |
| DE602004014772D1 (de) | 2008-08-14 |
| WO2005005416A1 (en) | 2005-01-20 |
| JP2007521313A (ja) | 2007-08-02 |
| HK1088318A1 (en) | 2006-11-03 |
| US20060189663A1 (en) | 2006-08-24 |
| AU2004256000A1 (en) | 2005-01-20 |
| KR20060034284A (ko) | 2006-04-21 |
| AU2004256000B2 (en) | 2007-07-26 |
| IS8291A (is) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640134A2 (es) | Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x | |
| CO6160291A2 (es) | Compuestos que modulan al receptor cb2 | |
| WO2006087476A3 (fr) | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| RS52243B (en) | HETEROCYCLIC MELT INHIBITORS AND PROCEDURES FOR THEIR USE | |
| IN2012DN04853A (es) | ||
| ATE474837T1 (de) | Prostaglandin analoge als ep4 rezeptor agonisten | |
| CO6160323A2 (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales | |
| NO20082579L (no) | Aza-substituert spiroderivat | |
| MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
| HRP20090533T1 (en) | Indolyl derivatives as liver-x-receptor modulators | |
| CR7950A (es) | Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| TW200617003A (en) | Viral polymerase inhibitors | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| TW200728298A (en) | Thiophene compounds and thrombopoietin receptor activators | |
| NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
| CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
| ATE417841T1 (de) | Furanderivate als ep4-rezeptorantagonisten | |
| ATE396183T1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
| CO5650235A2 (es) | Derivados de imidazol | |
| ATE510829T1 (de) | Neue verbindungen als adenosin-a1-rezeptor- antagonisten | |
| WO2008116185A3 (en) | Substituted pyrimidines as adenosine receptor antagonists | |
| AR075586A1 (es) | Proceso, purificacion y cristalizacion de 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea, inhibidor de pi3k/mtor | |
| TW200517387A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
| TNSN07439A1 (en) | Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |